Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00118287 · ClinicalTrials.gov registry record · Phase 1
Azacitidine and Etanercept in Treating Patients With Myelodysplastic Syndromes
A Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT00118287 is a Phase 1 study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 32 participants.
The verdict
NCT00118287, a Phase 1 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This phase I/II trial studies how well giving azacitidine together with etanercept works in treating patients with myelodysplastic syndromes (MDS). Drugs used in chemotherapy, such as azacitidine, works in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Chemoprotective drugs, such as etanercept, may protect normal cells from the side effects of chemotherapy
Interventions
- DRUG azacitidine
- BIOLOGICAL etanercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2005-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00118287
The ClinicalTrials.gov registry entry for NCT00118287 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which azacitidine is the first listed.
NCT00118287 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00118287 about?
NCT00118287 is a clinical study titled "Azacitidine and Etanercept in Treating Patients With Myelodysplastic Syndromes". This phase I/II trial studies how well giving azacitidine together with etanercept works in treating patients with myelodysplastic syndromes (MDS). Drugs used in chemotherapy, such as azacitidine, works in different ways to stop the growth of cancer cells, either by killing the cells or by stopping ...
What is the current status of trial NCT00118287?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2005-04.
What interventions are being tested in trial NCT00118287?
The interventions under investigation include: azacitidine (DRUG), etanercept (BIOLOGICAL).
Who is sponsoring clinical trial NCT00118287?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.